key: cord-1048956-ssqn4y3a
authors: Rakita, Uros; Kaundinya, Trisha; Guraya, Armaan; Nelson, Kamaria; Maner, Brittany; Manjunath, Jaya; Schwartzman, Gabrielle; Lane, Brittany; Silverberg, Jonathan I.
title: Atopic dermatitis is not associated with SARS-CoV-2 outcomes
date: 2021-09-17
journal: Arch Dermatol Res
DOI: 10.1007/s00403-021-02276-1
sha: 1835d2dd3ea272d534da9477757829619074f26f
doc_id: 1048956
cord_uid: ssqn4y3a

Atopic dermatitis is characterized by immune dysregulation, which may predispose toward worse COVID-19 outcomes. We conducted a retrospective cohort study to investigate the relationship of atopic dermatitis with COVID-19 symptom severity, hospitalization, length of hospital stay, requirement for oxygen therapy, long-term morbidity and mortality. Multivariable logistic regression models were constructed to examine the impact of atopic dermatitis (independent variable) on COVID-19 symptom severity, hospitalization, length of hospital stay, requirement for oxygen therapy, long-term morbidity and mortality (dependent variables). SARS-CoV-2 positive adult patients with diagnosed AD had similar odds of hospitalization (adjusted odds ratio [95% confidence interval]: 0.51 [0.20–1.35]), acute level of care at initial medical care (0.67 [0.35–1.30]), severe-critical SARS-CoV-2 (0.82 [0.29–2.30]), requirement of supplemental non-mechanical oxygen therapy (1.33 [0.50–3.58]), extended hospital stay (2.24 [0.36–13.85]), lingering COVID-19 symptoms (0.58 [0.06–5.31]) and COVID-19 death (0.002 [< 0.001– > 999]) compared to patients without AD. Our findings suggest AD is not an independent risk factor for COVID-19 severity or complications.

Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with systemic T-helper 2 activation and respiratory comorbidities, e.g. asthma and rhinitis. Concern exists regarding potential for poorer COVID-19 outcomes in AD patients, though previous studies had mixed findings [1] [2] [3] [4] [5] . We investigated the relationship between AD and COVID-19 outcomes in adults.

The study was approved by the George Washington University (GWU) institutional review board. We retrospectively analyzed data from GWU medical records for patients treated for SARS-CoV-2. Sociodemographic traits were compared between those with vs. without AD and severecritical vs. mild-moderate COVID-19 using chi-squared and student's t test for categorical and continuous variables, respectively (Table 1) . Binary logistic regression models were constructed with COVID-19 outcomes as dependent variables (acuity level of initial medical contact, hospitalization, hospitalization duration, COVID-19 symptom severity, requirement of supplemental oxygen therapy, mortality and 1 3 Table 1 Sociodemographic and other health-related associations related to diagnosis of atopic dermatitis Missing values were encountered in 3 (0.7%) for sex, 1 race (0.2%), 25 (5.8%) smoking, 1 (0.2%) insurance status. There were no missing values for immunosuppressant use, cancer diagnosis, AIDS diagnosis, CHF, OLD, Hypertension, CKD The other skin diseases included onychomycosis (n = 98), acne (n = 47), actinic keratosis (n = 16), allergic contact dermatitis (n = 18), alopecia unspecified (n = 52), basal cell carcinoma (n = 5), cutaneous lupus (n = 2), unspecified dermatitis (n = 25), dermatomyositis (n = 1), condyloma accuminata (n = 8), hand dermatitis (n = 7), hemangioma (n = 2), herpes simplex infection (n = 32), herpes zoster infection (n = 8), hidradenitis suppurativa (n = 15), hirsutism (n = 8), hyperhidrosis (n = 10), impetigo (n = 2), irritant contact dermatitis (n = 8), melanoma (n = 1), paronychia (n = 1), pityriasis rosea (n = 1), plantar wart (n = 11), psoriasis (n = 11), prurigo nodularis (n = 1), rosacea (n = 9), scabies (n = 1), seborrheic dermatitis (n = 39), seborrheic keratosis (n = 22), squamous cell carcinoma (n = 3), tinea (n = 53) and urticaria (n = 17) 

These findings are consistent with studies that found no association of AD with COVID-19 morbidity. AD patients may be more susceptible to acquiring SARS-CoV-2 infection [3] , though findings are inconclusive [5] . Current evidence indicates that AD patients are not at increased risk of mechanical ventilation [3, 4] , hospitalization [2] , longer hospital stay [4] , intensive care unit admission [4] or death [2, 4] . In one retrospective study, AD was inversely associated with COVID-19 hospitalization [1] . We further demonstrate that AD is not associated with various other COVID-19 outcomes, including supplemental oxygen therapy, lingering symptoms and acuity level of initial care.

Study strengths include examination of multiple COVID-19 outcomes and controlling for confounders in multivariable analyses. Limitations include small sample size of AD patients, recruitment from a single metropolitan academic center, racial homogeneity and lack of stratified analysis by SARS-CoV-2 variants or AD features. Future studies with larger samples can further elucidate potential associations between AD and COVID-19. + Fisher exact test used to calculate significance in instances when 25% of cells had frequencies < 5 *Chi-squared test **t test # Cancer diagnosis includes solid tumor, leukemia and lymphoma. Specific diagnosis and cancer treatment status not available ## Immunosuppressant drugs (n; % of total dataset) included adalimumab (n = 4; 0.93%), azathioprine (n = 2;0.47%), cyclosporine (n = 1; 0.23%), dupilumab (n = 1, 0.23%), etanercept (n = 1, 0.23%), hydroxychloroquine (n = 20; 4.65%), infliximab (n = 3;0.7%), ixekizumab (n = 1; 0.23%), methotrexate (n = 12;2.79%), methylprednisolone (n = 8;1.86%), mycophenolate mofetil (n = 8; 1.86%), prednisone (n = 49;11.4%), rituximab (n = 1;0.23%), sirolimus (n = 1; 0.23%), tacrolimus (n = 8; 1.86%), tofacitinib (n = 1; 0.23%), other (n = 7; 1.63%) 

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Table 2 Association of atopic dermatitis with COVID-19 severity and hospitalization # Binary logistic regression models were constructed with atopic dermatitis diagnosis as the independent variable and COVID-19 outcomes as the dependent variables. Dependent variables included hospitalization (yes vs. no), visit type (inpatient vs. outpatient), oxygen therapy (yes vs. no), COVID-19 severity (severe-critical vs. asymptomatic-mild) and hospital duration (1-6 days vs ≥ 7 days) ## Multinomial logistic regression models were constructed with atopic dermatitis diagnosis as the independent variable (yes/no) and COVID-19 course as the dependent outcome variable (chronic complications or death vs recovered). Crude odds ratios (OR) and 95% confidence intervals (CI) were generated for unadjusted models Adjusted OR and 95% CI were generated for age [ 

Atopy is predictive of a decreased need for hospitalization for coronavirus disease 2019

SARS-CoV-2 infection in patients with atopic dermatitis: a cross-sectional study

Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies

Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study

Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single centre, cross-sectional study